FP16.05 - CBM Identifies Novel Biomarkers to Inform Combination Platinum Compound Therapy in NSCLC

P70.20 - Impact of KRAS and Co-occurring Mutations on NSCLC Master Regulator Network as Determined by CBM

P12.06 - CBM Identifies PD-L1 Immunotherapy Response Criteria Based on Genomic Signature of NSCLC

P70.03 - CBM Identifies Amplifications of Chromosome 6p to Predict Chemotherapy Resistance